|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's Range||36.56 - 37.04|
|52 Week Range||29.00 - 42.82|
|Beta (3Y Monthly)||0.03|
|PE Ratio (TTM)||26.30|
|Forward Dividend & Yield||0.29 (0.79%)|
|1y Target Est||31.94|
Dr. Reddy's (RDY) announced that it has entered a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC to sell its neurology branded products.
Dr. Reddy’s Laboratories Limited announces that it has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC , pursuant to which Dr.
Strategic Acquisition Diversifies Company's Portfolio and Provides New Options for Migraine Patients MAPLE GROVE, Minn. , June 13, 2019 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today ...
Investment banker Barclays announced it has initiated coverage of 20 U.S. specialty pharmaceuticals stocks.But which 20 stocks within this sector are we talking about today? They include generic drugs companies Mylan (MYL), which Barclays rates Overweight (i.e. 'buy') and Teva Pharmaceutical Industries (TEVA), which the analyst rates Underweight (i.e. 'sell'), as well as: * Amneal Pharmaceuticals (AMRX) * Endo International (ENDP) * Reddy's Laboratories (RDY) * and Mallinckrodt plc (MNK)Each of which is rated Equal weight (i.e. 'hold').Within the animal health sector (i.e. veterinary medicine), Barclays initiates coverage with Overweight ratings on Zoetis (ZTS) and Kindred Biosciences (KIN), but gives Phibro Animal Health Corporation (PAHC) an Underweight rating.Among developmental and commercial stage companies "with unique products & segments," Barclays has two 'sells' -- Allergan (AGN) and Evolus (EOLS) -- and one hold: Ligand Pharmaceuticals (LGND). As for Barclays' 'buy' ratings, it rates the following companies Overweight ratings: * AMAG Pharmaceuticals (AMAG) * Jazz Pharmaceuticals (JAZZ) * Osmotica Pharmaceuticals (OSMT) * Coherus BioSciences (CHRS) * Pacira BioSciences (PCRX) * Revance Therapeutics (RVNC) * Bausch Health Companies (BHC) * and Foamix Pharmaceuticals (FOMX)Today, we really only have time to glance at just one of these stocks: Rehovot, Israel-based Foamix.Foamix is a late clinical-stage specialty pharmaceutical company focusing on foam-based medications for the treatment of acne and rosacea. Foamix stands out in this report primarily by virtue of the extremely high hopes Barclays' has for it, namely, valued at just $2.53 per share today, Barclays believes that within a year, Foamix stock will be selling for $10 -- a four-bagger in just one year.Why is Barclays so optimistic? As the analyst explains, Foamix is on the cusp of becoming a "commercial stage company" -- i.e. a company with actual revenue from sales, a rarity in small drugs stocks -- thanks to its topical Minocycline product for acne and rosacea. Designated "FMX-101" for acne treatment and "FMX-103" for rosacea, both these foam-based products "combine [the] proven efficacy of minocycline with a more tolerable side effect profile" says Barclays. From $3 million in annual revenue today, the banker predicts Foamix could do as much as $272 million in annual sales by 2025E.Considering that the entire company has a market cap of barely half that number -- $138 million -- today, Foamix at least seems to have earned its place on Barclays' list.Foamix has a few upcoming catalysts that could send its shares surging higher: * There is a scheduled PDUFA for FMX-101 on October 20, 2019. This is a key event for Foamix, as FMX-101 is its lead product in acne. * Foamix anticipates filing an NDA in mid-2019 for FMX-103 in moderate-to-severe papulopustular rosacea. * FCD-105 Phase II study initiation in mid-2019: FCD-105 is another pipeline product being evaluated in patients with acne and is a foam-based combination of minocycline and adapalene."We value Foamix on a DCF basis, assuming an 11.5% discount rate and a 3% terminal growth. We include risk adjusted pipeline values for both FMX-101 (90% probability of success) and FMX-103 (70% probability of success). We also assume base uptake of FMX-101, reaching 2025 risk-adj. sales of ~$200mm. This scenario yields a value of ~$10/share and serves as the basis for our price target," Barclays noted.Read more: Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now More recent articles from Smarter Analyst: * Should Investors Buy Facebook (FB) Stock After Its Cryptocurrency Launch? Top Analyst Weighs In * Avoid Canopy Growth Stock Like the Plague; Here’s Why * Hexo: When the Bulls Aren’t Bullish Enough * Market Delays Can Derail Aurora Cannabis (ACB) Stock
Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.
Dr. Reddy’s Laboratories Ltd. announced positive topline results from its Phase 2b study of PPC-06 in patients with moderate to severe plaque psoriasis.
BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.
Dr. Reddy’s Laboratories Limited today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended March 31, 2019 was filed with the United States Securities and Exchange Commission on June 3, 2019.
Dr. Reddy’s Laboratories Ltd. today announced the re-launch of Zenatane® , 10 mg, 20 mg, 30 mg and 40 mg, a therapeutic equivalent generic version of Accutane®, approved by the U.S.
Dr. Reddy's Laboratories (NYSE:RDY) reported its quarterly earnings figures on Friday, bringing in a profit that increased year-over-year and revenue that came in ahead of what Wall Street projected in its consensus guidance, yet RDY stock took a step back.The India-based business announced that for its fourth quarter of its fiscal 2019, it raked in earnings of 38 cents per ADS, which was roughly 12 cents higher than the company's profit from the same period in its fiscal 2018. Its revenue also impressed, coming in at $581 million for the three-month period.This amount was 13.7% higher than it was during the year-ago quarter for Dr. Reddy's, while also topping the Zacks Investment Research, which foresaw the company raking in sales of $565.45 million. Revenue from the company's Global Generics segment was up 9% year-over-year, while the Pharmaceutical Services and Active Ingredients segment saw sales surge 8% year-over-year.InvestorPlace - Stock Market News, Stock Advice & Trading TipsDr. Reddy's added that its Proprietary Products segment gained 139% year-over-year. For the fiscal year, the company brought in sales of $2.2 billion, gaining 8.3% when compared to the year-ago quarter.Earnings for its fiscal 2019 tallied up to $1.64 per ADS, marking a whopping gain of 92.9% when compared to the year-ago quarter.RDY stock is down about 1.6% on Friday despite the company unveiling quarterly earnings results that came in ahead of what Wall Street called for in its consensus estimate. Shares had been gaining 0.2% during pre-market trading. More From InvestorPlace * 7 Stocks to Buy that Lost 10% Last Week * 6 Chinese Stocks That Could Pop On a Trade Deal * 10 Retirement Stocks That Won't Wilt in a Bear Market Compare Brokers The post Dr. Reddy's Laboratories Earnings: RDY Stock Dips Despite Q4 Beat appeared first on InvestorPlace.
Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2019 under International Financial Reporting Standards .
Dr. Reddy’s Laboratories Ltd. today announced the launch of Daptomycin for Injection, 500mg/vial single-dose vial, a therapeutic equivalent generic version of Cubicin® for Injection, approved by the U.S.
Dr. Reddy's (RDY) will provide updates on new generic filings and new drug applications, when it reports fourth-quarter fiscal 2019 results.
Dr. Reddy’s Laboratories Ltd. today announced the launch of Testosterone Gel 1.62%, a therapeutic equivalent generic version of AndroGel® 1.62%, approved by the U.S.
NEW YORK , May 1, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City ...
Before we spend days researching a stock idea we'd like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 13.5% in the fourth quarter. Seven out of 11 industry groups in the S&P 500 Index were down more than 20% from their 52-week […]
Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.
Dr. Reddy’s Laboratories Ltd. announced today that it has entered into a definitive agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications in the U.S.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...
With economic growth slowing worldwide in 2019, investors looking for growth sources have been forced to get creative. Ongoing concerns about the outcome of the Sino-American trade war have clouded the outlook for the Chinese market, but India has the sixth-largest economy in the world and is expected to grow by 7.3 percent this year, according to the International Monetary Fund. Unreliable Numbers? Unfortunately for India investors, growth projections are dropping worldwide — and India may be no exception.
Dr. Reddy’s Laboratories Limited , through its wholly owned subsidiary Promius Pharma, LLC, announces the sale of its rights for SERNIVO® Spray, 0.05% and assignment of its rights to market and distribute, PROMISEB® Topical Cream and TRIANEX® 0.05% in the United States, to Encore Dermatology.